Kura Oncology, Inc. (NASDAQ:KURA) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued to investors on Thursday.
According to Zacks, “Kura Oncology, Inc. is a biopharmaceutical company. The company is involved in the discovery and development of therapeutics for the treatment of tumors and blood cancers. Its product pipeline includes small molecule drug candidates which are in different clinical trial consists of Tipifarnib-HRAS, Tipifarnib-PTCL, ERK inhibitor program and Menin MLL inhibitor program. Kura Oncology, Inc. is headquartered in La Jolla, California. “
Several other brokerages also recently issued reports on KURA. Oppenheimer Holdings, Inc. reaffirmed an “outperform” rating and issued a $16.00 price objective on shares of Kura Oncology in a research report on Friday, April 21st. Citigroup Inc. set a $13.00 price objective on shares of Kura Oncology and gave the company a “buy” rating in a research report on Tuesday. Leerink Swann reaffirmed an “outperform” rating and issued a $18.00 price objective (up previously from $16.00) on shares of Kura Oncology in a research report on Thursday. Finally, Cann reaffirmed a “buy” rating and issued a $16.00 price objective on shares of Kura Oncology in a research report on Monday, May 15th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $14.60.
Kura Oncology (NASDAQ:KURA) traded down 28.02% on Thursday, reaching $6.55. 544,165 shares of the company’s stock traded hands. The firm’s market capitalization is $140.00 million. The stock has a 50-day moving average of $9.13 and a 200 day moving average of $8.64. Kura Oncology has a 52 week low of $4.00 and a 52 week high of $12.10.
Kura Oncology (NASDAQ:KURA) last issued its quarterly earnings data on Monday, August 7th. The company reported ($0.40) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.43) by $0.03. On average, equities analysts expect that Kura Oncology will post ($1.64) EPS for the current fiscal year.
Several hedge funds have recently added to or reduced their stakes in KURA. State of Wisconsin Investment Board bought a new stake in Kura Oncology during the second quarter worth $102,000. Oppenheimer & Co. Inc. increased its stake in Kura Oncology by 14.7% in the first quarter. Oppenheimer & Co. Inc. now owns 12,500 shares of the company’s stock worth $110,000 after buying an additional 1,600 shares during the last quarter. Segantii Capital Management Ltd bought a new stake in Kura Oncology during the first quarter worth $120,000. Rhumbline Advisers bought a new stake in Kura Oncology during the second quarter worth $131,000. Finally, Nationwide Fund Advisors bought a new stake in Kura Oncology during the first quarter worth $136,000. 50.17% of the stock is owned by institutional investors and hedge funds.
Kura Oncology Company Profile
Kura Oncology, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kura Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.